ProTide generated long-acting abacavir nanoformulations

Zhiyi Lin; Nagsen Gautam; Yazen Alnouti; Joellyn McMillan; Aditya N. Bade; Howard E. Gendelman; Benson Edagwa

doi:10.1039/c8cc04708a

ProTide generated long-acting abacavir nanoformulations

Zhiyi Lin, Nagsen Gautam, Yazen Alnouti, Joellyn McMillan, Aditya N. Bade, Howard E. Gendelman, Benson Edagwa

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

Abacavir pronucleotide nanoformulations (NM3ABC) were prepared as a novel long acting slow effective release antiretroviral therapy. Single NM3ABC treatment of human monocyte-derived macrophages produced sustained intracellular carbovir-triphosphate and antiretroviral activities for up to 30 days.

Original language	English (US)
Pages (from-to)	8371-8374
Number of pages	4
Journal	Chemical Communications
Volume	54
Issue number	60
DOIs	https://doi.org/10.1039/c8cc04708a
State	Published - 2018

ASJC Scopus subject areas

Catalysis
Electronic, Optical and Magnetic Materials
Ceramics and Composites
General Chemistry
Surfaces, Coatings and Films
Metals and Alloys
Materials Chemistry

Access to Document

10.1039/c8cc04708a

Cite this

@article{cc807dff60d44a14ad9af4aa64c2ceec,

title = "ProTide generated long-acting abacavir nanoformulations",

abstract = "Abacavir pronucleotide nanoformulations (NM3ABC) were prepared as a novel long acting slow effective release antiretroviral therapy. Single NM3ABC treatment of human monocyte-derived macrophages produced sustained intracellular carbovir-triphosphate and antiretroviral activities for up to 30 days.",

author = "Zhiyi Lin and Nagsen Gautam and Yazen Alnouti and Joellyn McMillan and Bade, {Aditya N.} and Gendelman, {Howard E.} and Benson Edagwa",

note = "Funding Information: The research was supported by the University of Nebraska Foundation and the National Institutes of Health grants R01 MH104147, P01 DA028555, R01 NS36126, P01 NS31492, 2R01 NS034239, P01 MH64570, P30 MH062261, P30 AI078498, and R01 AG043540. Publisher Copyright: {\textcopyright} 2018 The Royal Society of Chemistry.",

year = "2018",

doi = "10.1039/c8cc04708a",

language = "English (US)",

volume = "54",

pages = "8371--8374",

journal = "Chemical Communications",

issn = "1359-7345",

publisher = "Royal Society of Chemistry",

number = "60",

}

TY - JOUR

T1 - ProTide generated long-acting abacavir nanoformulations

AU - Lin, Zhiyi

AU - Gautam, Nagsen

AU - Alnouti, Yazen

AU - McMillan, Joellyn

AU - Bade, Aditya N.

AU - Gendelman, Howard E.

AU - Edagwa, Benson

N1 - Funding Information: The research was supported by the University of Nebraska Foundation and the National Institutes of Health grants R01 MH104147, P01 DA028555, R01 NS36126, P01 NS31492, 2R01 NS034239, P01 MH64570, P30 MH062261, P30 AI078498, and R01 AG043540. Publisher Copyright: © 2018 The Royal Society of Chemistry.

PY - 2018

Y1 - 2018

N2 - Abacavir pronucleotide nanoformulations (NM3ABC) were prepared as a novel long acting slow effective release antiretroviral therapy. Single NM3ABC treatment of human monocyte-derived macrophages produced sustained intracellular carbovir-triphosphate and antiretroviral activities for up to 30 days.

AB - Abacavir pronucleotide nanoformulations (NM3ABC) were prepared as a novel long acting slow effective release antiretroviral therapy. Single NM3ABC treatment of human monocyte-derived macrophages produced sustained intracellular carbovir-triphosphate and antiretroviral activities for up to 30 days.

UR - http://www.scopus.com/inward/record.url?scp=85050655613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050655613&partnerID=8YFLogxK

U2 - 10.1039/c8cc04708a

DO - 10.1039/c8cc04708a

M3 - Article

C2 - 29995046

AN - SCOPUS:85050655613

SN - 1359-7345

VL - 54

SP - 8371

EP - 8374

JO - Chemical Communications

JF - Chemical Communications

IS - 60

ER -

ProTide generated long-acting abacavir nanoformulations

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this